Interpretation of Iron Studies During Oral Supplementation

Understanding the Laboratory Pattern

In inflammatory conditions, ferritin can be falsely elevated while transferrin saturation becomes the more reliable indicator of true iron availability for red blood cell production, according to the American College of Physicians 1, 2, 3

Measure hemoglobin at 2-4 weeks to confirm adequate response to oral iron, with a rise of ≥10 g/L (≥1 g/dL) indicating a positive response, as recommended by the American College of Physicians 3
Check C-reactive protein to determine if inflammation is causing ferritin elevation and functional iron deficiency, as suggested by the American College of Physicians 2, 3
Verify current TSAT value, as a TSAT <20% confirms inadequate iron availability for erythropoiesis regardless of ferritin level, according to the National Kidney Foundation 4, 1

If hemoglobin fails to increase or TSAT remains <20%, switch to intravenous iron in patients with hemoglobin <10 g/dL, previous intolerance to oral iron, evidence of inflammation with functional iron deficiency, or chronic kidney disease requiring erythropoiesis-stimulating agents, as recommended by the American College of Physicians 3
Target ferritin ≥100 ng/mL and TSAT ≥20% in patients with chronic kidney disease, as suggested by the National Kidney Foundation 4

The declining TSAT is more concerning than the rising ferritin in this clinical scenario, and in patients with chronic kidney disease, maintaining TSAT ≥20% is essential for optimal erythropoiesis, according to the National Kidney Foundation 4, 2
Iron deficiency is defined as ferritin <100 ng/mL and/or TSAT <20% in non-dialysis CKD patients, as defined by the National Kidney Foundation 4

Recheck complete iron panel (ferritin, TSAT, hemoglobin) plus CRP at the 4-week mark from initiation, as recommended by the American College of Physicians 3
Maintain target TSAT ≥20% and ferritin ≥100 ng/mL to optimize response to any concurrent erythropoiesis-stimulating therapy in patients with chronic kidney disease, according to the National Kidney Foundation 4